The global recombinant cell culture supplements market is estimated to be USD 0.838 billion in 2024 and is expected to reach USD 3.17 billion by 2035, with a CAGR of 12.86% during the forecast period 2025-2035. The market will grow due to a number of factors, including the growing demand for biologics and biosimilars, technological advancements in cell culture, the shift towards animal-free and ethical cell culture media, supportive government initiatives and funding, and strategic alliances and collaborations.
Technological advancements in cell culture processes have facilitated the development of more sophisticated recombinant supplements, which significantly enhance cell growth, productivity, and overall yield. These recombinant supplements - such as recombinant insulin, transferrin, and albumin - are increasingly employed to optimize cell culture conditions, reduce variability, and ensure reproducibility in biomanufacturing. Furthermore, Jazz Pharmaceuticals plc declared in April 2024 that it and its associates will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place in Chicago from May 31 to June 4, 2024. In addition to a poster outlining the research design for the ongoing JZP898 Phase 1 trial, the presentations will include results from trials employing zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). This illustrates how recombinant technology and advances in clinical research continue to work in tandem.
By product, the recombinant albumin segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the increasing demand for animal-free and high-purity supplements in biopharmaceutical production, which helps enhance cell growth and stability while reducing the risk of contamination. For instance, in July 2024, the European Investment Fund gave €350 million ($379 million) to Kembara's deeptech and climate fund, and Flagship Pioneering increased its capital base by an impressive $3.6 billion to support 25 innovative companies in "human health, sustainability, and artificial intelligence." Additionally, the recombinant cytokines segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising use in cell therapy, immunotherapy, and stem cell research to promote cell differentiation and immune cell activation.
By application, the Biopharmaceutical production segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the expanding pipeline of biologics and biosimilars, which require optimized cell culture conditions to maximize yield and quality. For instance, November 2023 Presenting two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9, 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12, and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3, Jazz Pharmaceuticals plc announced today. For HER2+/HR+ metastatic breast cancer (mBC), new information includes revised results from a Phase 2a trial of the experimental HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free treatment option. Additionally, the regenerative medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to its growing adoption in stem cell research and tissue engineering, driven by the demand for innovative therapies to treat degenerative diseases.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the significant investment in R&D for biologics and vaccines, requiring high-quality cell culture supplements for efficient production processes. For instance, April 2022 Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that they have signed a licensing agreement whereby Jazz will have the exclusive worldwide development and commercialization rights to Werewolf's investigational WTX-613, a unique, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule. Additionally, the CDMOs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of biomanufacturing activities by pharmaceutical companies to enhance scalability and reduce operational costs.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established biopharmaceutical industry, significant investment in R&D, and the presence of major market players driving the adoption of advanced recombinant cell culture technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of the biotechnology sector, increasing government support for biomanufacturing, and a rising focus on biosimilars and regenerative medicine in emerging economies like China and India. For instance, in February 2023 Chiesi Global Rare Diseases, a division of Chiesi Farmaceutici S.p.A., a global healthcare organization focused on research (Chiesi Group), announced today that Lamzede® (velmanase alfa-tycv) has received FDA approval to treat pediatric and adult patients with non-central nervous system manifestations of alpha-mannosidosis (AM). AM is a rare and progressive lysosomal storage illness that is brought on by a lack of the enzyme α-mannosidase.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Technological advancements in cell culture processes have facilitated the development of more sophisticated recombinant supplements, which significantly enhance cell growth, productivity, and overall yield. These recombinant supplements - such as recombinant insulin, transferrin, and albumin - are increasingly employed to optimize cell culture conditions, reduce variability, and ensure reproducibility in biomanufacturing. Furthermore, Jazz Pharmaceuticals plc declared in April 2024 that it and its associates will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place in Chicago from May 31 to June 4, 2024. In addition to a poster outlining the research design for the ongoing JZP898 Phase 1 trial, the presentations will include results from trials employing zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). This illustrates how recombinant technology and advances in clinical research continue to work in tandem.
By product, the recombinant albumin segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the increasing demand for animal-free and high-purity supplements in biopharmaceutical production, which helps enhance cell growth and stability while reducing the risk of contamination. For instance, in July 2024, the European Investment Fund gave €350 million ($379 million) to Kembara's deeptech and climate fund, and Flagship Pioneering increased its capital base by an impressive $3.6 billion to support 25 innovative companies in "human health, sustainability, and artificial intelligence." Additionally, the recombinant cytokines segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising use in cell therapy, immunotherapy, and stem cell research to promote cell differentiation and immune cell activation.
By application, the Biopharmaceutical production segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the expanding pipeline of biologics and biosimilars, which require optimized cell culture conditions to maximize yield and quality. For instance, November 2023 Presenting two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9, 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12, and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3, Jazz Pharmaceuticals plc announced today. For HER2+/HR+ metastatic breast cancer (mBC), new information includes revised results from a Phase 2a trial of the experimental HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free treatment option. Additionally, the regenerative medicine segment is predicted to grow at the fastest CAGR during the forecast period owing to its growing adoption in stem cell research and tissue engineering, driven by the demand for innovative therapies to treat degenerative diseases.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global recombinant cell culture supplements market in 2024 owing to the significant investment in R&D for biologics and vaccines, requiring high-quality cell culture supplements for efficient production processes. For instance, April 2022 Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that they have signed a licensing agreement whereby Jazz will have the exclusive worldwide development and commercialization rights to Werewolf's investigational WTX-613, a unique, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule. Additionally, the CDMOs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of biomanufacturing activities by pharmaceutical companies to enhance scalability and reduce operational costs.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established biopharmaceutical industry, significant investment in R&D, and the presence of major market players driving the adoption of advanced recombinant cell culture technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of the biotechnology sector, increasing government support for biomanufacturing, and a rising focus on biosimilars and regenerative medicine in emerging economies like China and India. For instance, in February 2023 Chiesi Global Rare Diseases, a division of Chiesi Farmaceutici S.p.A., a global healthcare organization focused on research (Chiesi Group), announced today that Lamzede® (velmanase alfa-tycv) has received FDA approval to treat pediatric and adult patients with non-central nervous system manifestations of alpha-mannosidosis (AM). AM is a rare and progressive lysosomal storage illness that is brought on by a lack of the enzyme α-mannosidase.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Recombinant Cell Culture Supplements Market Report 2024 - 2035
Recombinant Cell Culture Supplements Market Analysis & Forecast by Product 2024 - 2035 (Revenue USD Bn)
- Recombinant Albumin
- Recombinant Insulin
- Recombinant Transferrin
- Recombinant Cytokines
- Others
Recombinant Cell Culture Supplements Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Biopharmaceutical Production
- Regenerative Medicine
- Other Applications
Recombinant Cell Culture Supplements Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Pharmaceutical & Biotechnology Companies
- Cell Culture Media Manufacturers
- CMOs & CROs
- CDMOs
- Academic Research Institutes
Recombinant Cell Culture Supplements Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Recombinant Cell Culture Supplements Market: Product Estimates & Trend Analysis
8. Recombinant Cell Culture Supplements Market: Application Estimates & Trend Analysis
9. Recombinant Cell Culture Supplements Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Recombinant Cell Culture Supplements Market
12. Europe Global Recombinant Cell Culture Supplements Market
13. Asia Pacific Global Recombinant Cell Culture Supplements Market
14. Latin America Global Recombinant Cell Culture Supplements Market
15. MEA Global Recombinant Cell Culture Supplements Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific
- Lonza Group
- Merck Group (MilliporeSigma)
- Becton Dickinson and Company (BD)
- Repligen Corporation
- Fujifilm Irvine Scientific
- Sigma-Aldrich (part of Merck)
- General Electric (GE Healthcare)
- Waters Corporation
- Eppendorf AG
- Agilent Technologies
- Samsung Biologics
- CellGenix GmbH
- ProBioGen AG
- Nutricia (Danone)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.84 Billion |
| Forecasted Market Value ( USD | $ 3.17 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
